FLECARDIA Διάλυμα για ένεση/έχχυση
Sponsors
Win Medica Pharmaceutical A.E., Win Medica Pharmaceutical S.A.
Conditions
Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%Restoration of sinus rhythm in patients with recent AF onset
Phase 3
Comparison of the effectiveness of IntraVenous FLECainide plus oral ranolazine versus intravenous flecainide alone in the cardioversion of recent onset atrial fibrillation - a randomized, prospective, multicentre, open-label study, the IV-FLEC study.
CompletedCTIS2024-514677-22-00
Start: 2023-03-23End: 2025-05-30Target: 210Updated: 2025-02-11
A perspective multicenter randomized clinical trial for the safety and efficacy of flecainide compared to amiodorone for the conversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary disease without residual ischemia and ejection fraction >35% (FLECA-ED)
RecruitingCTIS2024-519233-33-00
Start: 2023-04-13Target: 200Updated: 2025-10-03